Cambridge Quantum Computing (CQC) is pleased to announce their collaboration with Roche, to design and implement noisy-intermediate-scale-
The multi-year collaboration will combine the industry-leading expertise of both CQC and Roche to significantly advance the application of quantum computing to pharmaceutical relevant problems– accelerating the industry closer towards quantum advantage.
The collaboration will employ CQC’s leading quantum chemistry platform, “EUMEN,” to augment the Alzheimer’s Disease research efforts of Roche. The collaboration will be recognized as one of the most substantive research efforts in the field of quantum computing to date, and strives to enable the development of next generation, quantum inspired therapeutics.
Ilyas Khan, CEO of CQC said, “For many years quantum computing has held out great promise for discovering new therapeutics that aid humanity in fighting some of the most devastating and damaging diseases. We are pleased that due to the careful and pioneering efforts of our research teams, some of this promise is starting to come to fruition. We are excited to collaborate with Roche and their quantum computing taskforce. It is a true privilege to collaborate in pursuit of quantum advantage.”